QX 005N
Alternative Names: QX-005N; SNC005; SNCA 005Latest Information Update: 15 Feb 2023
At a glance
- Originator Qyuns Therapeutics
- Class Anti-inflammatories; Antiallergics; Antiasthmatics; Antihistamines; Monoclonal antibodies; Skin disorder therapies
- Mechanism of Action Interleukin 4 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Atopic dermatitis; Prurigo nodularis; Rhinosinusitis
- Phase I Asthma
- Discontinued Allergic rhinitis
Most Recent Events
- 14 Feb 2023 Discontinued - Preclinical for Allergic rhinitis in China (Parenteral)
- 14 Feb 2023 Phase-I clinical trials in Asthma in China (Parenteral) (Qyuns Therapeutics pipeline, February 2023)
- 14 Feb 2023 Phase-II clinical trials in Atopic dermatitis in China (SC) (Qyuns Therapeutics pipeline, February 2023)